PTSD treatment

In the winter of 2023, combat medic Ihor Kholodylo faced a life-altering event on Ukraine’s eastern front. A shell from a Russian tank struck his medical evacuation van, leaving him severely injured. Though Kholodylo survived, the psychological toll was profound. Despite healing from physical...

An average of 17 veterans committed suicide per day in 2020 according to the Dept of Veterans Affairs. The percentage of veterans from conflicts in the Middle East who have experienced PTSD is nearly triple the number of those from the Vietnam War. Suicide is the second leading cause of death among...

Yale University and Transcend Therapeutics, a rapid-acting psychedelic therapies developer, received a three-year collaborative grant from the U.S. Dept. of Defense (DoD) for a total of $1 million to support their preclinical research on methylone.  The research will assess Transcend...

The long-awaited psychedelic-assisted treatment alternative for Post-Traumatic Stress Disorder (PTSD) is moving closer to federal approval.  The Multidisciplinary Association for Psychedelic Studies (MAPS) and its private subsidiary company, MAPS PBC shared the publication of the...

Silo Pharma (NASDAQ: SILO), a developmental-stage biopharma company merging traditional therapeutics with psychedelic research, has advanced the formulation development for its ketamine-composed drug SPC-15.  The company aims to combine the liquid nasal formulation and SPC-15’s novel...

The GOP-controlled House of Representatives recently passed two amendments of a comprehensive Military Construction, Veterans Affairs and Related Agencies (MilCon/VA) spending bill. One would allow VA doctors to recommend medical cannabis to veterans, and the other would promote research into...

On May 1, new partners Canadian psychedelics developer PharmAla Biotech and Australian digital healthcare business Vitura Health (formerly Cronos Australia) announced the definitive establishment of a 50-50 joint venture Cortexa.  On May 20, the CEOs of both PharmAla and Vitura hosted a...

Psychedelics biotech Silo Pharma Inc. (NASDAQ: SILO) and Columbia University are developing a novel compound formulation as a prophylactic treatment for stress, anxiety and PTSD. Ketamine-based SPC-15 is currently undergoing studies on dosage and delivery methods. These, coupled with published...

Zinger Keypoints: Long-term (over 1 year) follow-up reflects lasting improvements in symptom severity. Data confirms prior Phase 2 studies on MDMA-assisted therapy’s sustained effect on PTSD treatment. New Drug Application (NDA) to be submitted in Q3 2023 would be the last...

Awakn Life Sciences Corp. (OTCQB: AWKNF) has signed a licensing partnership agreement in Europe with a Portugal-based healthcare consortium currently operating in stealth mode.   This is the first time Awakn, a psychedelics biotech and services provider, will license its protocols...

Lifesciences biotech company Psycheceutical Bioscience (OTC: BWVI), of which Benzinga’s advisory council member Zappy Zapolin is Chief Visionary Officer, patented a topical ketamine formulation to treat PTSD. The patent includes related methods using drug delivery technology NeuroDirect....

This article was originally published on Psychedelic Spotlight and appears here with permission. Research will focus on how various psychedelics can be used under proper supervision and guidance to treat severe depression, anxiety and PTSD. Is Texas poised to become a hub for psychedelic research?...

The state of Michigan is funding two major medical cannabis research projects to the tune of $20 million with tax revenue from the state’s recreational marijuana program, announced Michigan’s Marijuana Regulatory Agency (MRA). And There's No Shortage Of Cannabis Cash In...